Medicamen Biotech Ltd vs Vivanza Biosciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Medicamen Biotech Ltd is ₹ 267.4 as of 18 May 15:30 . The P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 86.2 on March 2025 . This represents a CAGR of 9.89% over 5 yearsThe P/E Ratio of Vivanza Biosciences Ltd changed from 687.4 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years The Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 612.46 crore on March 2025 . This represents a CAGR of -1.25% over 5 yearsThe Market Cap of Vivanza Biosciences Ltd changed from ₹ 52.24 crore on March 2021 to ₹ 7.96 crore on March 2025 . This represents a CAGR of -31.36% over 5 years The revenue of Medicamen Biotech Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 47.44 crore. This represent the decline of -100% The revenue of Vivanza Biosciences Ltd for the Mar '26 is ₹ 6.37 crore as compare to the Dec '25 revenue of ₹ 45.33 crore. This represent the decline of -85.95% The ebitda of Medicamen Biotech Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 4.91 crore. This represent the decline of -100% The ebitda of Vivanza Biosciences Ltd for the Mar '26 is ₹ -0.22 crore as compare to the Dec '25 ebitda of ₹ 0.29 crore. This represent the decline of -175% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Vivanza Biosciences Ltd changed from ₹ 0.27 crore to ₹ -0.45 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 13.45 % on March 2025 . This represents a CAGR of 6.58% over 5 yearsThe Dividend Payout of Vivanza Biosciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

About Vivanza Biosciences Ltd

Vivanza Biosciences Limited, formerly known as Ivee Injectaa Limited was established in March, 1982 as a Private Limited Company and was converted into a Public Limited Company in May, 1992.
Due to recessionary trends which lead to difficult business conditions in year 1999-2000, the parenteral industry suffered a setback and due to this, the name of the Company was changed from Ivee Injectaa Limited to Vivanza Biosciences Limited in 2015. The Company is focused in commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines.
It is presently engaged in the business of Pharmaceutical Products. Head quartered in Gujarat, India, Company came into existence in April 2016 to further spread its wings in global market with global quality pharmaceutical products at competitive pricing system.

FAQs for the comparison of Medicamen Biotech Ltd and Vivanza Biosciences Ltd

Which company has a larger market capitalization, Medicamen Biotech Ltd or Vivanza Biosciences Ltd?

Market cap of Medicamen Biotech Ltd is 379 Cr while Market cap of Vivanza Biosciences Ltd is 7 Cr

What are the key factors driving the stock performance of Medicamen Biotech Ltd and Vivanza Biosciences Ltd?

The stock performance of Medicamen Biotech Ltd and Vivanza Biosciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Medicamen Biotech Ltd and Vivanza Biosciences Ltd?

As of May 18, 2026, the Medicamen Biotech Ltd stock price is INR ₹280.15. On the other hand, Vivanza Biosciences Ltd stock price is INR ₹1.94.

How do dividend payouts of Medicamen Biotech Ltd and Vivanza Biosciences Ltd compare?

To compare the dividend payouts of Medicamen Biotech Ltd and Vivanza Biosciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.